The Efficacy and Cost-Effectiveness of Umeclidinium/Vilanterol versus Tiotropium in Symptomatic Patients with Chronic Obstructive Pulmonary Disease

Figure 7

Cost-effectiveness plane for the incremental costs in US dollars compared with the incremental effectiveness in QALYs. Each dot represents a separate run of the model with different input values for each variable randomly selected according to their distribution. According to the Chinese healthcare system, the probability of UMEC/VI being cost-effective was 61.6% at a willingness-to-pay of $31554/QALY.